Literature DB >> 33031752

MIS-C: post-infectious syndrome or persistent infection?

Michael Schwartz1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33031752      PMCID: PMC7535622          DOI: 10.1016/S1473-3099(20)30786-6

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


× No keyword cloud information.
Li Jiang and colleagues provided an exceptional Review of multisystem inflammatory syndrome in children (MIS-C). However, the possibility that MIS-C is more consistent with a subacute infection than a post-infectious syndrome was not fully considered. Weisberg and colleagues and Jia and colleagues reported reduced severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody breadth, specificity, and neutralising activity in patients with MIS-C compared with patients with COVID-19 respiratory infection. Weisberg and colleagues postulated that “because younger individuals have increased number of naive T cells in different sites to respond to new pathogens, it is possible that a robust T cell response efficaciously clears infection in the lung preventing severe respiratory disease in children, and a low level, persistent infection in other sites may build up over time in some children, resulting in MIS-C.” ACE-2 receptors are abundantly present in arterial and venous endothelial cells and arterial smooth muscle cells, and the vascular system is a possible sight of persistent SARS-CoV-2 infection. Colmenero and colleagues, in a study of seven children with chilblains, confirmed the presence of viral particles by immunohistiochemistry and electron microscopy in dermal vascular endothelium. Similar to patients with MIS-C, these patients presented approximately 4 weeks after the peak of COVID-19 in their home region, had no personal history of acute COVID-19, and were negative by nasopharyngeal RT-PCR testing. The report by Diorio and colleagues of extensive burr cells (echinocytes) in the peripheral blood smears of patients with MIS-C provides an additional clue to the pathophysiology of this recently described and unique syndrome. Activated macrophages induce nitrosative stress, which can induce echinocyte formation. Burr cell formation has also been reported in Epstein-Barr virus-triggered secondary haemophagocytic lymphohistiocytosis, and the tumour necrosis factor-α and interleukin-10 elevation described by the CHOP group is primarily produced by macrophage or monocyte lineages. In MIS-C, immune responses that have not fully controlled an ongoing infection might allow persistent activation of the intrinsic immune system. This persistent innate immune inflammatory response probably occurs because of the ability of SARS-CoV-2 to block type 1 and type 3 interferon response signalling to the adaptive immune system without disrupting cytokine production. Thankfully, most children with MIS-C recover after treatment with aspirin, corticosteroids, and immunoglobulin. Elucidation of the pathophysiology of MIS-C will inform the treatment of children who are non-responsive to standard therapy. If MIS-C is confirmed to be caused by ongoing infection, this finding might also have important implications for antiviral treatment of adults with prolonged symptoms after SARS-CoV-2 infection.
  5 in total

1.  Epstein-barr virus-induced hemophagocytic lymphohistiocytosis.

Authors:  K Goudarzipour; M Kajiyazdi; A Mahdaviyani
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2013

2.  Mild Cytokine Elevation, Moderate CD4+ T Cell Response and Abundant Antibody Production in Children with COVID-19.

Authors:  Ran Jia; Xiangshi Wang; Pengcheng Liu; Xiaozhen Liang; Yanling Ge; He Tian; Hailing Chang; Hao Zhou; Mei Zeng; Jin Xu
Journal:  Virol Sin       Date:  2020-07-22       Impact factor: 4.327

3.  SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases.

Authors:  I Colmenero; C Santonja; M Alonso-Riaño; L Noguera-Morel; A Hernández-Martín; D Andina; T Wiesner; J L Rodríguez-Peralto; L Requena; A Torrelo
Journal:  Br J Dermatol       Date:  2020-08-05       Impact factor: 11.113

4.  Multisystem inflammatory syndrome in children and COVID-19 are distinct presentations of SARS-CoV-2.

Authors:  Caroline Diorio; Sarah E Henrickson; Laura A Vella; Kevin O McNerney; Julie Chase; Chakkapong Burudpakdee; Jessica H Lee; Cristina Jasen; Fran Balamuth; David M Barrett; Brenda L Banwell; Kathrin M Bernt; Allison M Blatz; Kathleen Chiotos; Brian T Fisher; Julie C Fitzgerald; Jeffrey S Gerber; Kandace Gollomp; Christopher Gray; Stephan A Grupp; Rebecca M Harris; Todd J Kilbaugh; Audrey R Odom John; Michele Lambert; Emily J Liebling; Michele E Paessler; Whitney Petrosa; Charles Phillips; Anne F Reilly; Neil D Romberg; Alix Seif; Deborah A Sesok-Pizzini; Kathleen E Sullivan; Julie Vardaro; Edward M Behrens; David T Teachey; Hamid Bassiri
Journal:  J Clin Invest       Date:  2020-11-02       Impact factor: 14.808

Review 5.  COVID-19 and multisystem inflammatory syndrome in children and adolescents.

Authors:  Li Jiang; Kun Tang; Mike Levin; Omar Irfan; Shaun K Morris; Karen Wilson; Jonathan D Klein; Zulfiqar A Bhutta
Journal:  Lancet Infect Dis       Date:  2020-08-17       Impact factor: 71.421

  5 in total
  3 in total

Review 1.  Epidemiology, Clinical Features, and Outcomes of Multisystem Inflammatory Syndrome in Children (MIS-C) and Adolescents-a Live Systematic Review and Meta-analysis.

Authors:  Li Jiang; Kun Tang; Omar Irfan; Xuan Li; Enyao Zhang; Zulfiqar Bhutta
Journal:  Curr Pediatr Rep       Date:  2022-05-06

2.  SARS-CoV-2-related multisystem inflammatory syndrome in an immunocompromised child with leukemia.

Authors:  Ambreen Pandrowala; Honey Panchal; Sangeeta Mudaliar; Minnie Bodhanwala; Shakuntala Prabhu; Shreepal Jain; Jayashree Mishra; Prashant Hiwarkar
Journal:  Pediatr Blood Cancer       Date:  2021-03-04       Impact factor: 3.838

Review 3.  Multisystem inflammatory syndrome in children

Authors:  Selda Hançerli Törün; Dilek Yilmaz Çiftdoğan; Ateş Kara
Journal:  Turk J Med Sci       Date:  2021-12-17       Impact factor: 0.973

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.